Article Details
Retrieved on: 2025-01-20 21:07:14
Tags for this article:
Click the tags to see associated articles and topics
Summary
The article highlights the extension of Poxel SA's patent for Imeglimin in China, focusing on type 2 diabetes and related kidney diseases. This aligns with the biotech key concept by addressing metabolic disorders through innovative treatments.
Article found on: www.biospace.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here